Niemann-Pick disease type C (NPC) is a lysosomal storage disorder with disrupted intracellular cholesterol trafficking. HP-β-CD is a cholesterol solubilizer
100% of patients who completed the trial improved or remained stable, and 89% met the efficacy outcome measure of improvement
HPβCD as a treatment for Niemann-Pick Type C1 disease can reduce some debilitating symptoms and extend life span, but the
Cyclo Therapeutics, Inc., a clinical stage biotechnology company developing cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C and
Transaction Includes Uplisting to Nasdaq and Reverse Stock Split Cyclo Therapeutics, Inc., a clinical stage biotechnology company developing a cyclodextrin
Niemann-Pick Disease Type C (NPC) is a severe neurovisceral disorder that is pathophysiologically characterized by intracellular transport abnormalities leading to
Cyclo Therapeutics, a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC)
Strategic drug repurposing in combination with rapid testing of established molecular targets could provide a pause in disease progression and
Cyclo Therapeutics reported the publication of an international patent application for the treatment of Alzheimer’s disease with HPBCD.
A paper has recently come out open-access in Biomacromolecules reporting on pH-Responsive Polymersome Microparticles as Smart Cyclodextrin-Releasing Agents (DOI: 10.1021/acs.biomac.9b01083).